Oncology, endocrinology and sexual-health teams get a survivorship update on testosterone deficiency after cancer treatment. Androgen deprivation therapy, chemotherapy, immunotherapy and orchidectomy are linked to fatigue, hot flushes, sexual symptoms, bone health, metabolic risk and the distinction between primary and secondary hypogonadism.

Oncology and primary-care clinicians get practical lifestyle guidance for prostate cancer, including during metastatic disease and androgen-deprivation therapy. Graded aerobic activity, resistance work, prehabilitation and peer support are linked to fatigue, weight change, sarcopenia, cardiovascular health, treatment tolerance and preservation of patient agency.

Oncology, primary-care and sexual-health clinicians get a patient-centred view of advanced prostate cancer. Long-term hormone therapy, fatigue, mood, body image, sexual function and exercise goals are connected to proactive holistic assessment, shared decisions and better continuity between specialist and community care.

Oncology, gynaecology and primary-care teams get survivorship guidance for menopause after cancer treatment. It covers active symptom screening, tumour-specific HRT risk assessment, post-treatment review, bone health, lifestyle measures and clear oncology input when ongoing prescribing moves into primary care.

Oncology, gynaecology and menopause-care clinicians get a symptom-led approach to cancer treatment-induced menopause. Ovarian surgery, chemotherapy or pelvic radiotherapy may cause vasomotor, sleep, mood, sexual, urogenital, fatigue and cognitive symptoms requiring individualised HRT, vaginal oestrogen or non-hormonal decisions.

Oncology and gynaecology teams get a treatment-sequencing update for platinum-resistant ovarian cancer. Folate receptor alpha testing, mirvetuximab soravtansine, ocular toxicity, immunotherapy combinations, glucocorticoid receptor antagonism, response need and time toxicity all shape patient-centred decisions.

Oncology clinicians and educators get a practical framework for explaining treatment benefit, recurrence and toxicity. It prioritises absolute risk, natural frequencies, common denominators, visual aids and teach-back while keeping frailty, competing mortality, quality of life and patient goals within shared decision-making.

For neuro-oncology teams, glioblastoma gene therapy brings tumour heterogeneity into trial conversations. This links TGX-007, ADePT, convection-enhanced delivery, tissue endpoints and early phase safety monitoring without assuming that striking mouse survival results translate directly to humans.

Pancreatic radiotherapy decisions need selection, local-control goals and toxicity planning made explicit. SABR and adaptive image guidance sit close to stomach, duodenum, bowel and vasculature, so pain, nausea, bleeding, perforation, diabetes and malabsorption require planned review.

Pancreatic cancer radiotherapy is presented as palliation, consolidation after systemic therapy, neoadjuvant treatment in selected borderline resectable disease and possible oligometastatic control. The clinical decision is selection: metastatic status, chemotherapy response, luminal gastrointestinal invasion, nutritional burden and realistic treatment goals.